Differentiation-inducing factor-1 (DIF-1) inhibits STAT3 activity involved in gastric cancer cell proliferation via MEK-ERK-dependent pathway
Masashi Kanai(Kyoto University Hospital), Tsutomu Chiba(Kyoto University), Naoki Kanda(Jichi Medical University), Toshio Nakajima(Kyoto University), Yoshitaka Konda(Kyoto University), Apichart Nanakin(Kyoto University), Yoshio Izumi(Kyoto University), Yuzuru Kubohara(Juntendo University)
Cited by 87
Related Papers
STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells
|Oncogene|2004|306
Randomized phase <scp>III</scp> study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (<scp>KHBO1401</scp>‐ <scp>MITSUBA</scp>)
|Journal of Hepato-Biliary-Pancreatic Sciences|2022|244
A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin®) in cancer patients
|Cancer Chemotherapy and Pharmacology|2013|191
Serum miR-21, miR-29a, and miR-125b Are Promising Biomarkers for the Early Detection of Colorectal Neoplasia
|Clinical Cancer Research|2015|157